ALL ABOUT IBOGAINE PART 1, 2, 3

ALL ABOUT IBOGA-INE: A 3-PART CONVERSATION WITH EXPERTS

ZOOM LINK

Join us Thursday April 23, 30, and May 7, 11:30 am to 1:30 pm MTN for a panel discussion about ibogaine and iboga

Hosted by Awake.net & GITA (Global Ibogaine Therapy Alliance)

SPEAKERS
Garyth Moxey, Patrick and Michelle Fishley, Anders Beatty, Dr. Deborah Mash, Barry Rossinoff, Martie Underwood, Tobias Erny, Tracy Ganske, Lakshmi Narayan, Ian Mackenna, Chris Jenks, Lori Shindel more to come.

TOPICS
We will discuss biology and origin, best practices, chemistry, mechanism of action, the inner journey, neuro-regeneration, challenges with other medications and new analogs, ensuring safety, cardiac risk, AND also the tribal and ceremonial traditions, rite of passage, meaning and purpose, the chemistry of ibogaine vs iboga, voacanga, the challenges and cautions of scaling it, but also the necessity for a scalable solution, and last but not least preparation and integration.

PART 1 April 23rd Meeting summary doc

PART 1 RECORDING WITH CHAT

https://us06web.zoom.us/rec/share/hRnZyYNCEkp4ANaBsZSFapTLH6vjwqmBEXb_ttg9ZlZuzRJ8OAk71Hvd4REDIAAj.Sb9YH5GkLVTz_iaX?startTime=1776965445000

Key takeaways

Ibogaine is a powerful medicine for treating addiction, TBI, and PTSD, but it is not a “magic bullet” and requires comprehensive preparation, medical screening, and integration support

Cardiac screening (EKG, QT interval monitoring) and drug interaction assessment are critical for safe ibogaine treatment due to complex pharmacological interactions

Treatment protocols are evolving, with SR-17018 showing promise for tapering patients off difficult substances like fentanyl, 7-OH, and kratom before ibogaine treatment

The medicine works best when patients approach it with humility, intentionality, and willingness to engage in their own healing process

Sustainability concerns exist around iboga bark harvesting; voacanga africana offers an alternative source for ibogaine production

Integration and aftercare are essential components, with the “pink cloud” period lasting approximately 3 months post-treatment due to noribogaine metabolite

President Trump’s recent executive order has brought national attention to ibogaine, creating opportunities and challenges for responsible scaling